AstraZeneca debuts development programme for BRILINTA®

pharmafield logo - pharma news

AstraZeneca has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor (BRILINTA®) in rare emergency situations.

MEDI2452 is being developed by MedImmune, AstraZeneca’s biologics research and development arm. 

Marc Ditmarsch, Global Development Lead for BRILINTA, said: “In certain emergencies, doctors need to have the option to swiftly reverse the effects of oral antiplatelet agents, in order to enable emergency surgery or a quick response to a major bleeding event without having to wait for the effects of the medicine to wear off. Currently there are no FDA approved medications to counteract the antiplatelet effect in these situations.

“If the circumstances demand it, we believe MEDI2452 has the potential to help address this need for patients treated with BRILINTA.”

The development of MEDI2452 sits alongside the wider PARTHENON clinical programme for BRILINTA, which includes five registration studies involving around 80,000 patients across the broad spectrum of atherothrombotic disease. 

PEGASUS-TIMI 54 aims to assess the efficacy and safety of ticagrelor (twice daily compared to placebo on a background of low-dose aspirin), for the long-term prevention of atherothrombotic events in patients, aged 50 and older, who suffered a heart attack one to three years prior to study enrolment, and who have one additional cardiovascular risk factor.

The study, involving over 21,000 patients, will be the next one within the programme to complete, with top line results expected in the first quarter of 2015. 

“Current guidelines generally recommend 12 months of dual antiplatelet therapy following an acute coronary syndrome event, however atherothrombotic disease is a chronic, progressive and in some cases fatal condition,” Mr Ditmarsch said. 

“The PEGASUS trial will help us evaluate the potential long-term benefit of therapy with ticagrelor for the chronic condition. This will be important information for patients with a history of myocardial infarction and their physicians, to determine the management of their condition following a heart attack beyond 12 months.”